Brief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
30/09/2026 12:06
BRIEF-Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc) Sept 30 (Reuters) - Rafael Holdings Inc RFL.N:
RAFAEL HOLDINGS ANNOUNCES TOPLINE RESULTS FROM THE PIVOTAL PHASE 3 TRANSPORTNPC™ STUDY OF TRAPPSOL® CYCLO™ IN NIEMANN-PICK DISEASE TYPE C (NPC)
RAFAEL - COMPANY ON TRACK TO SUBMIT NDA FOR TRAPPSOL CYCLO IN Q4 2026
RAFAEL - TRAPPSOL CYCLO DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 96
RAFAEL - TRAPPSOL CYCLO DEMONSTRATES WELL-TOLERATED SAFETY PROFILE WITH NO NEW SAFETY SIGNALS
Source text: ID:nGNX9rBghd
Further company coverage: RFL.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million